The low lymphocyte count is being watched long term as well not just at leukopheresis because full recovery does not always occur and that would be expected to affect outcomes in an immunotherapy trial. Just because a minimum threshold is reached does not mean this represents an optimum situation. The fact that low ALC is not exclusionary to longer term response is important and any attempt to discount this takes away from an accurate assessment of predicted treatment effect in comparison to inclusion/exclusion trial criteria from other trials. Best wishes.
Market Data 
Markets 
AI
